3rd Next Generation RNA Therapeutics Summit | May 7-9,, 2024 | Boston, MA

Pioneering the Next Breakthrough in Durable and Potent RNA Therapeutics for Patients

The field of next generation RNA therapeutics continues to progress towards clinical translation, with enormous investments and collaborations, such as Orbital Therapeutics’ recent $270 million Series A financing.

The 3rd Next Generation RNA Therapeutics Summit returns to cover the depth and breadth of the next of generation RNAs, including circular RNA, self-amplifying RNA (saRNA) and beyond from discovery to clinic and towards scalable manufacturing, unlocking the huge therapeutic and commercial potential of this emerging class of modalities.

Join 120+ expert leaders in Discovery, R AND D, Engineering, Preclinical Translation and CMC from the key stakeholders pioneering advances in RNA technologies and continue to fast-track these next generation therapies into the clinic, and towards patients faster.


URLs:
Website: https://go.evvnt.com/2128086-0?pid=10018
Tickets: https://go.evvnt.com/2128086-2?pid=10018
Brochure: https://go.evvnt.com/2128086-3?pid=10018

Prices:
Drug Developer - Conference + 3 Workshops - On The Door: USD 4197.00,
Drug Developer - Conference + 2 Workshops - On The Door: USD 3797.00,
Drug Developer - Conference + 1 Workshop - On The Door: USD 3398.00,
Drug Developer - Conference Only - On The Door: USD 2999.00,
Service Provider - Conference + 3 Workshops - On The Door: USD 5097.00,
Service Provider - Conference + 2 Workshops - On The Door: USD 4631.00,
Service Provider - Conference + 1 Workshop - On The Door: USD 4166.00,
Service Provider - Conference Only - On The Door: USD 3699.00


Speakers: Dharini Shah, Senior Director, Sanofi, Dinesh Chandra, Associate Director, JNJ, Francis Poulin, Vice President - eRNA Science and Analytical Development, Laronde, Gilles Besin, Chief Scientific Officer, Orbital Therapeutics, Hernando Lopez, Assistant Professor, Johns Hopkins University, James ferguson, Chief Medical Officer, Matinas BioPharma, Joanna Sztuba-Solinska, Principal Scientist, Pfizer, Justin Letendre, Synthetic Biology Scientist, Strand Therapeutics, Nathaniel Wang, Chief Executive Officer and Co-Founder, Replicate Bioscience, Rachel Groppo, Director, Self-Amplifying RNA Team Lead, Johnson and Johnson Innovative Medicine, Raphael Townshend, Founder and Chief Executive Officer, Atomic AI, Stephany Tzeng, Research Associate, The Johns Hopkins University School of Medicine, Victor Levitsky, Chief Scientific Officer, Circio Holding ASA, Zelanna Goldberg, Chief Medical Officer, Replicate Bioscience